Pus7-KO Mouse
Common Name
Pus7-KO
제품 ID
S-KO-18768
Backgroud
C57BL/6JCya
품종 계통계통 ID
KOCMP-78697-Pus7-B6J-VA
상태
이 마우스 계통을 논문에서 사용할 경우, “Pus7-KO Mouse (카탈로그 번호 S-KO-18768)은 Cyagen에서 구입하였습니다.”라고 명시해 주시기 바랍니다.
구매 가능한 제품 종류
연령
Genotype
성별
수량
표준 제공 조건은 최소 3마리의 이형접합(heterozygous) 보균자를 보장합니다. 동형접합(homozygous) 보균자 및/또는 특정 성별에 대한 브리딩 서비스도 제공됩니다.
기본 정보
품종 계통
Pus7-KO
품종 계통계통 ID
KOCMP-78697-Pus7-B6J-VA
유전자명
제품 ID
S-KO-18768
유전자 별칭
C330017I15Rik
배경
C57BL/6JCya
NCBI ID
변형 내용
Conventional knockout
염색체
Chr 5
Phenotype
Datasheet
적용 분야
--
품종 계통 설명
Ensembl 전사체 ID
ENSMUST00000131992
NCBI 전사체 ID
NM_001289781
타겟 영역
Exon 5
유효 영역 크기
~1.4 kb
유전자 연구 개요
Pus7, known as Pseudouridine synthase 7, is an enzyme crucial for pseudouridylation, a post-transcriptional RNA modification. Pseudouridine is the most frequent epitranscriptomic modification, influencing RNA function and gene expression [1,2,5,7,8]. Pus7 is involved in various biological processes such as translational control, especially in stem cells where it modifies tRNA-derived fragments to impact stem cell commitment [5]. It is also associated with multiple disease-related pathways, making it an important target for understanding disease mechanisms.
In glioblastoma, high Pus7 expression is associated with worse patient survival, and its expression and catalytic activity are required for glioblastoma stem cell tumorigenesis. Inhibition of Pus7 suppresses tRNA pseudouridylation, tumorigenesis, and extends the lifespan of tumor-bearing mice [1,4].
In gastric cancer, Pus7 is reduced in tumor tissues. It inhibits gastric cancer cell proliferation and tumor growth by enhancing the translation efficiency of ALKBH3 mRNA through pseudouridylation [2].
In colorectal cancer, Pus7 promotes cell proliferation by directly stabilizing SIRT1 to activate the Wnt/β-catenin pathway [3]. Also, HSP90-dependent Pus7 overexpression facilitates CRC cell metastasis by regulating LASP1 abundance [10].
In human patients, Pus7 deficiency causes a neurodevelopmental phenotype due to dysregulated protein translation [6]. Pan-cancer analysis shows Pus7 is overexpressed in most malignancies, contributing to poor prognosis in several cancer types, and is a potential biomarker and therapeutic target for osteosarcoma [7]. It also affects pre-mRNA processing by co-transcriptional pseudouridylation [8] and is involved in host-SARS-CoV-2 RNA interactions [9].
In conclusion, Pus7 plays essential roles in translational control and is closely associated with various diseases, especially cancer. The use of gene-knockout or conditional-knockout models in research has significantly contributed to understanding how Pus7 functions in disease-related biological processes, providing potential therapeutic strategies for glioblastoma, gastric cancer, colorectal cancer, and other malignancies, as well as insights into neurodevelopmental disorders.
References:
1. Cui, Qi, Yin, Kailin, Zhang, Xiaoting, Yi, Chengqi, Shi, Yanhong. 2021. Targeting PUS7 suppresses tRNA pseudouridylation and glioblastoma tumorigenesis. In Nature cancer, 2, 932-949. doi:10.1038/s43018-021-00238-0. https://pubmed.ncbi.nlm.nih.gov/35121864/
2. Chang, Yongxia, Jin, Hao, Cui, Yun, Xie, Shanshan, Zhou, Tianhua. . PUS7-dependent pseudouridylation of ALKBH3 mRNA inhibits gastric cancer progression. In Clinical and translational medicine, 14, e1811. doi:10.1002/ctm2.1811. https://pubmed.ncbi.nlm.nih.gov/39175405/
3. Zhang, Qi, Fei, Sujuan, Zhao, Yanchao, Lu, Lili, Chen, Weichang. 2022. PUS7 promotes the proliferation of colorectal cancer cells by directly stabilizing SIRT1 to activate the Wnt/β-catenin pathway. In Molecular carcinogenesis, 62, 160-173. doi:10.1002/mc.23473. https://pubmed.ncbi.nlm.nih.gov/36222184/
4. Zhang, Daniel Y, Ming, Guo-Li, Song, Hongjun. 2021. PUS7: a targetable epitranscriptomic regulator of glioblastoma growth. In Trends in pharmacological sciences, 42, 976-978. doi:10.1016/j.tips.2021.10.002. https://pubmed.ncbi.nlm.nih.gov/34657723/
5. Guzzi, Nicola, Cieśla, Maciej, Ngoc, Phuong Cao Thi, Hsieh, Andrew C, Bellodi, Cristian. 2018. Pseudouridylation of tRNA-Derived Fragments Steers Translational Control in Stem Cells. In Cell, 173, 1204-1216.e26. doi:10.1016/j.cell.2018.03.008. https://pubmed.ncbi.nlm.nih.gov/29628141/
6. Han, Sangwoo T, Kim, Andrew C, Garcia, Karolyn, Malicdan, May C, Tifft, Cynthia J. 2022. PUS7 deficiency in human patients causes profound neurodevelopmental phenotype by dysregulating protein translation. In Molecular genetics and metabolism, 135, 221-229. doi:10.1016/j.ymgme.2022.01.103. https://pubmed.ncbi.nlm.nih.gov/35144859/
7. Dong, Baokang, Wang, Binqi, Fan, Meng, Zhang, Jingyu, Zhao, Ziqin. 2024. Comprehensive analysis to identify PUS7 as a prognostic biomarker from pan-cancer analysis to osteosarcoma validation. In Aging, 16, 9188-9203. doi:10.18632/aging.205863. https://pubmed.ncbi.nlm.nih.gov/38819212/
8. Martinez, Nicole M, Su, Amanda, Burns, Margaret C, Yeo, Gene W, Gilbert, Wendy V. 2022. Pseudouridine synthases modify human pre-mRNA co-transcriptionally and affect pre-mRNA processing. In Molecular cell, 82, 645-659.e9. doi:10.1016/j.molcel.2021.12.023. https://pubmed.ncbi.nlm.nih.gov/35051350/
9. Giambruno, Roberto, Zacco, Elsa, Ugolini, Camilla, Tartaglia, Gian Gaetano, Nicassio, Francesco. 2023. Unveiling the role of PUS7-mediated pseudouridylation in host protein interactions specific for the SARS-CoV-2 RNA genome. In Molecular therapy. Nucleic acids, 34, 102052. doi:10.1016/j.omtn.2023.102052. https://pubmed.ncbi.nlm.nih.gov/38028201/
10. Song, Dan, Guo, Ming, Xu, Shuai, Wang, Shiqi, Zhao, Qingchuan. 2021. HSP90-dependent PUS7 overexpression facilitates the metastasis of colorectal cancer cells by regulating LASP1 abundance. In Journal of experimental & clinical cancer research : CR, 40, 170. doi:10.1186/s13046-021-01951-5. https://pubmed.ncbi.nlm.nih.gov/33990203/
품질 관리 기준
정자 검사
동결 보존 전: 정자 농도 측정 및 정자 생존율 평가.
동결 보존 후: 각 배치에서 동결 보존된 정자 바이알 1개를 선택하여 체외수정(in vitro fertilization)에 사용합니다.
Environmental Standards:
SPFAvailable Region:
GlobalSource:
Cyagen문의하기
맞춤형 동물 모델 관련 상담을 위해 Cyagen 전문가와 연락해 보세요. 아래 양식을 작성하여 상담을 시작하거나 견적을 요청하시기 바랍니다.
Cyagen은 고객님의 개인정보를 소중히 여깁니다. 최신 제품, 서비스 및 인사이트를 안내드리고자 합니다. 고객님의 수신 설정은 다음과 같습니다:
해당 커뮤니케이션은 언제든지 수신 거부하실 수 있습니다. 수신 거부 방법 및 데이터 보호에 대한 자세한 내용은 개인정보처리방침을 참고해 주시기 바랍니다.
아래 버튼을 클릭함으로써, 요청하신 콘텐츠 제공을 위해 본 양식을 통해 제출된 개인정보를 Cyagen이 저장 및 처리하는 데 동의하게 됩니다.
